Fasoracetam
| |||
| Names | |||
|---|---|---|---|
| IUPAC name
(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one | |||
| Identifiers | |||
110958-19-5  | |||
| ChEMBL | ChEMBL2106179  | ||
| ChemSpider | 171980 | ||
| Jmol interactive 3D | Image Image | ||
| KEGG | C13311 | ||
| PubChem | 198695 | ||
| |||
| |||
| Properties | |||
| C10H16N2O2 | |||
| Molar mass | 196.246 g/mol | ||
| Pharmacology | |||
| Oral | |||
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |||
| verify (what is ?) | |||
| Infobox references | |||
Fasoracetam (NS-105, 5-oxo-D-prolinepiperidinamide monohydrate) is a research chemical of the racetam family.[1]
Effects
Fasoracetam appears to act as a GABAB receptor antagonist. It has been shown to block memory disruptions caused by Baclofen, a GABA B agonist.[2] Fasoracetam upregulates GABA B receptors after repeat dosing.[3]
Fasoracetam may act as a mGluR agonist and research into the efficacy for treating ADHD and cognitive impairment is currently being conducted.[4] [5]
Similar to Coluracetam, Fasoracetam enhances high affinity choline reuptake (HACU). [2]
References
- ↑ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
- 1 2 "Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer.".
- ↑ "Effect of a novel cognition enhancer NS-105 on learned helplessness in rats: possible involvement of GABA(B) receptor up-regulation after repeated treatment.".
- ↑ "A novel cognition enhancer NS-105 modulates adenylate cyclase activity through metabotropic glutamate receptors in primary neuronal culture.".
- ↑ http://www.research.chop.edu/forms/btob/Oct12BtoB.pdf
This article is issued from Wikipedia - version of the Thursday, February 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.